SCHEMBL3528501

SCHEMBL3528501

CN1CCN(CC#Cc2cnc(N)c3c(-c4ccc(NC(=O)Nc5cccc(Cl)c5)cc4)csc23)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.75
AURKA O14965 16/20 0.75
LCK P06239 15/20 0.75
CSF1R P07333 15/20 0.75
FGFR1 P11362 15/20 0.75
NEK2 P51955 15/20 0.75
ROCK1 Q13464 15/20 0.75
NTRK2 Q16620 15/20 0.75
ABL1 P00519 14/20 0.75
FLT1 P17948 14/20 0.75
FLT3 P36888 14/20 0.75
ROCK2 O75116 14/20 0.75
MET P08581 13/20 0.75
KIT P10721 13/20 0.75
MAP4K4 O95819 13/20 0.75
TAOK1 Q7L7X3 13/20 0.75
PLK4 O00444 13/20 0.75
LYN P07948 13/20 0.75
RPS6KB1 P23443 13/20 0.75
EPHA2 P29317 13/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3525867 0.93 KDR (0.83) KDRAURKALCKCSF1RFGFR1
SCHEMBL3528843 0.92 KDR (0.89) KDRAURKALCKCSF1RFGFR1
SCHEMBL3526709 0.91 KDR (0.75) KDRAURKALCKCSF1RFGFR1
SCHEMBL3532921 0.89 LCK (0.72) KDRAURKALCKCSF1RFGFR1
SCHEMBL3534913 0.86 KDR (0.81) KDRAURKALCKCSF1RFGFR1
SCHEMBL3531034 0.86 KDR (1.00) KDRAURKALCKCSF1RFGFR1
SCHEMBL3532923 0.86 KDR (0.72) KDRAURKALCKCSF1RFGFR1
SCHEMBL3528141 0.85 CSF1R (0.70) KDRAURKALCKCSF1RFGFR1
SCHEMBL3524754 0.84 KDR (1.00) KDRAURKALCKCSF1RFGFR1
SCHEMBL3536159 0.84 KDR (0.84) KDRAURKALCKCSF1RFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885LCK 3/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885LCK 3/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885LCK 3/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKA 207/4885LCK 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.